<DOC>
	<DOCNO>NCT00984711</DOCNO>
	<brief_summary>This study design gather data regard efficacy safety Rituxan clinical practice whereby patient may present concomitant medical condition , medication well vary presentation rheumatoid arthritis always capture within `` purer '' population see industry sponsor clinical trial .</brief_summary>
	<brief_title>Observational Study Rituxan Rheumatoid Arthritis Patients Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Subjects active rheumatoid arthritis define ACR criterion &gt; 18 year age time consent Able start RITUXAN therapy per approve product monograph within approximately 30 day confirm enrollment Known Type 1 hypersensitivity anaphylactic reaction murine protein , Chinese Hamster Ovary cell proteins component RITXAN per approve Product monograph Presence significant uncontrolled medical condition , Investigator 's opinion , precludes use RITUXAN outline Product Monograph</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>